Medical professionals specializing in hepatology from five major liver societies worldwide, along with pharmaceutical representatives and regulatory officials, met in Barcelona earlier this year to develop a standardized definition for acute-on-chronic liver failure (ACLF). The effort addresses longstanding confusion among clinicians regarding how this condition differs from acute liver failure and how it should be managed across different healthcare systems.
Under the new consensus framework, patients must meet specific laboratory criteria to receive an ACLF diagnosis. A bilirubin level of at least 1.5 and an international normalized ratio (INR) of at least 5 establish baseline parameters. Bilirubin, a substance that accumulates when the liver cannot process it properly, and INR, which measures blood clotting capacity dependent on liver-produced proteins, serve as key indicators. Clinicians then evaluate potential dysfunction in the brain, kidneys, circulatory, and respiratory systems as additional markers of liver failure.
Previously, different regions employed distinct diagnostic approaches based on disease prevalence patterns. East Asian countries, where hepatitis B is more common, used different criteria than Western nations, where alcohol-related cirrhosis predominates. This fragmentation created barriers to consistent patient care, delayed treatment initiation, and complicated the development of new therapies and clinical trial standards. The distinction between acute liver failure, which occurs without underlying disease, and ACLF carries particular significance because existing transplant allocation policies in some countries prioritize acute liver failure patients differently.
The group’s consensus position paper, published in the journal Hepatology last month, provides guidance not only on diagnostic criteria but also on drug-induced liver injury management, transplant considerations, and standardized endpoints for pharmaceutical companies developing new treatments. Input from the U.S. Food and Drug Administration helped shape clinical trial benchmarks, ensuring that interventions could be properly evaluated and registered across jurisdictions. Stakeholders report satisfaction with the unified approach, viewing it as a foundation for improved patient outcomes and accelerated therapeutic development.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI